Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study.

@article{Dyke2007DeliveryOI,
  title={Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study.},
  author={Robert E Van Dyke and Kurt Nikander},
  journal={Respiratory care},
  year={2007},
  volume={52 2},
  pages={184-90}
}
BACKGROUND Iloprost (Ventavis) inhalation solution is approved in doses of 2.5 microg and 5.0 microg for treatment of pulmonary arterial hypertension (World Health Organization group I) in patients with New York Heart Association class III or IV symptoms, delivered with 2 Adaptive Aerosol Delivery (AAD) systems: Prodose and I-neb. The HaloLite device was the first-generation AAD system used in the clinical delivery of inhaled iloprost, and I-neb is the third-generation system. OBJECTIVE Study… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Precise dose delivery of salbutamol delivered using the I-neb AAD System

  • J Young, T. Dyche
  • Proc Drug Delivery to the Lungs XVI. Aerosol…
  • 2005

Bench performance and in vivo deposition efficiency of the I-neb adaptive aerosol delivery system (AAD) during tidal versus slow and deep breathing

  • GC Smaldone, K. Nikander
  • Proceedings of the Aerosol Society
  • 2004

Breathing patterns

  • K Nikander, J. Denyer
  • Eur Respir Rev
  • 2000

Standards in assessing in vitro nebulizer performance

  • JH Dennis, CA Pieron, O. Nerbrink
  • Eur Respir Rev
  • 2000

Adaptive aerosol delivery in practice

  • J. Denyer
  • Eur Respir Rev
  • 1997

Similar Papers

Loading similar papers…